Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer

Figure 1 Human epidermal growth factor receptor 2 gene mutation site diagram. Created with BioRender.com (see Supplementary material).

Figure 2 Activation pathway of human epidermal growth factor receptor 2 gene in gastric cancer immunotherapy. Created with BioRender.com (see Supplementary material).

Figure 3 Mechanism of action of anti-human epidermal growth factor receptor 2 therapies in gastric cancer. Created with BioRender.com (see Supplementary material).

Figure 4 Strategies to overcome mutation-based TKI resistance. A: PDB: 5XFF; B: PDB: 4V01; C: PDB: 4R6V; D: PDB: 6JPJ. Created with BioRender.com (see Supplementary material).

Figure 5 Schematic diagram of TKI-FGFR pathway activation in gastric cancer cells. Created with BioRender.com (see Supplementary material).

Figure 6 Mechanisms of alternative signaling activation induced FGFR-TKI resistance in gastric cancer. Created with BioRender.com (see Supplementary material).

Figure 7 Schematic diagram of the effect of PD-1/CTLA-4 signaling on the immune microenvironment of gastric cancer. ICB: Immune checkpoint blockade; ADR: Adverse drug reaction; MHC: Major histocompatibility complex. Created with BioRender.com (see Supplementary material).